更新于：2024-11-04
Pemirolast Potassium
吡嘧司特钾
更新于：2024-11-04
概要
基本信息
非在研机构 |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构
分子式C10H8KN6O |
InChIKeyWXWWEFZPRLRGFL-UHFFFAOYSA-N |
CAS号100299-08-9 |
关联
2
项与 吡嘧司特钾 相关的临床试验吡嘧司特钾片人体生物等效性试验
吡嘧司特钾片人体生物等效性预试验
100 项与 吡嘧司特钾 相关的临床结果
登录后查看更多信息
100 项与 吡嘧司特钾 相关的转化医学
登录后查看更多信息
100 项与 吡嘧司特钾 相关的专利（医药）
登录后查看更多信息
107
项与 吡嘧司特钾 相关的文献（医药）2024-10-01BREAST CANCER RESEARCH AND TREATMENT
Comprehensive genomic profiling of ESR1, PIK3CA, AKT1, and PTEN in HR(+)HER2(−) metastatic breast cancer: prevalence along treatment course and predictive value for endocrine therapy resistance in real-world practice
Article
作者: Quintanilha, Julia C F ; Bhave, Manali A ; McArthur, Heather ; Kalinsky, Kevin ; Tukachinsky, Hanna ; Graf, Ryon P ; Huang, Richard S P ; Li, Gerald ; Ross, Jeffrey S ; Levy, Mia A ; Scott, Takara ; Pasquina, Lincoln
Abstract:
Background:
The treatment landscape for HR(+)HER2(−) metastatic breast cancer (MBC) is evolving for patients with ESR1 mutations (mut) and PI3K/AKT pathway genomic alterations (GA). We sought to inform clinical utility for comprehensive genomic profiling (CGP) using tissue (TBx) and liquid biopsies (LBx) in HR(+)HER2(−) MBC.
Methods:
Records from a de-identified breast cancer clinicogenomic database for patients who underwent TBx/LBx testing at Foundation Medicine during routine clinical care at ~ 280 US cancer clinics between 01/2011 and 09/2023 were assessed. GA prevalence [ESR1mut, PIK3CAmut, AKT1mut, PTENmut, and PTEN homozygous copy loss (PTENloss)] were calculated in TBx and LBx [stratified by ctDNA tumor fraction (TF)] during the first three lines of therapy. Real-world progression-free survival (rwPFS) and overall survival (rwOS) were compared between groups by Cox models adjusted for prognostic factors.
Results:
~ 60% of cases harbored 1 + GA in 1st-line TBx (1266/2154) or LBx TF ≥ 1% (80/126) and 26.5% (43/162) in LBx TF < 1%. ESR1mut was found in 8.1% TBx, 17.5% LBx TF ≥ 1%, and 4.9% LBx TF < 1% in 1st line, increasing to 59% in 3rd line (LBx TF ≥ 1%). PTENloss was detected at higher rates in TBx (4.3%) than LBx (1% in TF ≥ 1%). Patients receiving 1st-line aromatase inhibitor + CDK4/6 inhibitor (n = 573) with ESR1mut had less favorable rwPFS and rwOS versus ESR1 wild-type; no differences were observed for fulvestrant + CDK4/6 inhibitor (n = 348).
Conclusion:
Our study suggests obtaining TBx for CGP at time of de novo/recurrent diagnosis, followed by LBx for detecting acquired GA in 2nd + lines. Reflex TBx should be considered when ctDNA TF < 1%.
2024-10-01European Urology Oncology
Regional Versus Systematic Biopsy in Addition to Targeted Biopsy: Results from a Systematic Review and Meta-analysis
Review
作者: Tedde, Alessandro ; Madonia, Massimo ; Roupret, Morgan ; Schoots, Ivo ; Sanguedolce, Francesco ; Giannarini, Gianluca ; Palou, Joan ; Chernysheva, Daria ; Basile, Giuseppe ; Uleri, Alessandro ; Panebianco, Valeria ; Padhani, Anwar R ; Budeaus, Lars ; Padhani, Anwar R. ; Lauwers, Carol Nancy Gianna ; Baboudjian, Michael ; Breda, Alberto
BACKGROUND AND OBJECTIVE:
Intensification of targeted biopsy (TBx) around a magnetic resonance imaging (MRI)-visible lesion with regional biopsy (RBx) could obviate the need for systematic biopsy (SBx). We aimed to compare the detection yields of clinically significant prostate cancer (csPCa)-defined as International Society of Urological Pathology (ISUP) grade group ≥2-between TBx + RBx and the reference standard (TBx + SBx).
METHODS:
RBx was defined as perilesional or ipsilateral biopsy. A literature search was conducted up to September 2023 using PubMed, Embase, and Web of Science databases. The Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) guidelines were followed. Included studies were eligible when presenting data from SBx, TBx, and TBx + RBx cores and their detection yields. The Quality Assessment of Diagnostic Accuracy Studies (QUADAS-2) criteria were used to assess the risk of bias of the included studies.
KEY FINDINGS AND LIMITATIONS:
Twenty-one studies were included for a meta-analysis. The overall detection yield of csPCa was not statistically different between TBx + SBX and TBx + RBx (46.1% vs 44.2%; odds ratio [OR] 1.07, 95% confidence interval [CI] 0.99-1.16, p = 0.07); similar findings were found also for ISUP grade group ≥3 prostate cancer (PCa; OR 1.06, 95% CI 0.92-1.22, p = 0.43) and in different subgroup analyses. TBx + SBx was associated with higher cancer detection of ISUP grade group 1 PCa (OR 1.16, 95% CI 1.04-1.30, p = 0.008). The main limitations include the retrospective nature of most of the selected studies, heterogeneity of RBx definition, and template.
CONCLUSIONS AND CLINICAL IMPLICATIONS:
Our study supports the use of the TBx + RBx template in the early detection pathway for the detection of csPCa. SBx can be omitted when targeting lesions visible on MRI.
PATIENT SUMMARY:
A prostate biopsy strategy consisting of taking biopsy in and around an magnetic resonance imaging-visible lesion reduces the risk of detecting indolent prostate cancers without affecting the detection of aggressive tumours.
2024-09-01PROSTATE
Image‐guided multiparametric magnetic resonance imaging‐transrectal ultrasound fusion biopsy augmented with a sextant versus an extended template random biopsy: Comparison of cancer detection rates, complication and functional outcomes
Article
作者: Wolf, Steven ; Michael, Zoe ; Taha, Terek ; Polascik, Thomas J ; Ivey, Michael ; Kotamarti, Srinath ; Deivasigamani, Sriram ; Aminsharifi, Ali ; Gupta, Rajan T ; Mottaghi, Mahdi ; Adams, Eric S ; Seguier, Denis
Abstract:
Purpose:
To compare the efficacy of a novel fusion template “reduced six‐core systemic template and multiparametric magnetic resonance imaging/transrectal ultrasound (mpMRI/TRUS) fusion targeted biopsy” (TBx+6c), with mpMRI/TRUS fusion‐targeted biopsy and 12‐core systematic biopsy template (TBx+12c) in the diagnosis of prostate cancer (PCa).
Materials and Methods:
This is an institutional review board approved single‐center observational study involving adult men undergoing fusion‐targeted biopsies for the diagnosis of PCa. Patients were sorted into cohorts of TBx+6c or TBx+12c based on the systematic biopsy template used. The study's main objective was to determine the cancer detection rate (CDR) for overall PCa and clinically significant PCa (csPCa) and the secondary objectives were to compare complication rates and functional outcome differences between the cohort.
Results:
A total of 204 patients met study's inclusion criteria. TBx+6c group had 120 patients, while TBx+12c cohort had 84 patients. The groups had similar baseline characteristics and overall CDR in the TBx+6c cohort was 71.7% versus 79.8%, compared to the TBx+12c (p = 0.18) whereas, the csPCa detection rate in the TBx+6c group was 50.8% versus 54.8% in the TBx+12c group (p = 0.5). TBx+6c cohort had lower overall complication rate of 3% versus 13%, (p = 0.01) and ≥ grade 2 complication rates (1 (1%) vs. 3(4%), p = 0.03) compared to the TBx+12c cohort. There were no differences in IIEF‐5 (p = 0.5) or IPSS (p = 0.1) scores at baseline and 2‐weeks and 6‐weeks post‐biopsy.
Conclusion:
TBx+6c cohort, when compared to the TBx+12c cohort, demonstrated comparable diagnostic performance along with similar functional outcomes and lower complication rates. These results suggest the importance of further exploring the clinical implications of adopting a TBx+6c schema for PCa diagnosis in comparison to the widely used TBx+12c schema through a multicenter randomized controlled trial.
100 项与 吡嘧司特钾 相关的药物交易
登录后查看更多信息
研发状态
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 季节性过敏性鼻炎 | 日本 | 1995-01-20 | |
| 哮喘 | 日本 | 1981-01-18 | |
| 变应性结膜炎 | 日本 | 1981-01-18 | |
| 过敏性鼻炎 | 日本 | 1981-01-18 |
登录后查看更多信息
临床结果
临床结果
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用